Pharmaron invests $14m in private equity fund
Pharmaron Beijing (SZSE:300759) announced its participation in a new private equity investment, committing 100 million yuan (approximately $14 million USD) to the "Ningbo Yongkang Equity Investment Partnership," pending regulatory approval. The investment aims to leverage specialized expertise and promote the high-quality development of the pharmaceutical sector in Ningbo, China. Pharmaron will act as a limited partner. Shanghai Hongfu Private Equity Fund Management Co., Ltd. will serve as the general partner and fund manager. The total fundraising target for the fund is 500 million yuan. The fund will primarily focus on investments in private equity and venture capital funds managed by third parties, targeting projects in the life science sector in the Ningbo area.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Pharmaron Beijing publishes news
Free account required • Unsubscribe anytime